Press release from Evosep (Odense, Denmark). Introducing Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and drug development. Evosep (Odense, Denmark) announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale liquid chromatography–mass spectrometry (LC-MS)–based proteomics for research and pharmaceutical drug development. Success is materialized through ease of use and simplicity of comprehensive, standardized workflow solutions meeting today’s analytical requirements. The introduction of Evokit™ sample preparation kits and the Evosep™ Lupo™ Sample Preparation System, together with Evosep Eno™, establishes Evosep Proteomics: a unified sample-to-separation platform built for reproducibility, scalability and AI-ready proteomic insights. Building on its legacy of standardizing LC separation, Evosep now extends upstream to sample preparation, delivering complete sample-to-separation standardization across proteomics workflows. Proteomics stands at an inflection point. As biology becomes increasingly data-driven and studies grow in size and complexity, the field requires more than advances in instrumentation, it requires an ecosystem capable of delivering consistent, interoperable and high-confidence data across workflows and laboratories. Today’s fragmented processes, manual variability and inconsistent methods continue to limit scale and reproducibility, slowing the translation of proteomic insights into scientific and therapeutic impact. “To fully realize AI-driven drug development, LC-MS-based proteomics must become standardized. Our users have been asking for scalable proteomics, not only as a reliable analytical tool, but as an AI-ready data foundation for the next generation of drug discovery and development,” commented Morten Bern, CEO of Evosep. Evosep Proteomics addresses this need by delivering consistent proteomic output at scale, creating…
